Chlamydophila pneumonia vaccine - Antex Biologics

Drug Profile

Chlamydophila pneumonia vaccine - Antex Biologics

Alternative Names: TWARVAX

Latest Information Update: 25 Nov 2004

Price : $50

At a glance

  • Originator Antex Biologics
  • Class
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Chlamydial infections

Most Recent Events

  • 25 Nov 2004 Discontinued - Preclinical for Chlamydial infections in USA (unspecified route)
  • 25 Aug 2000 Antex has licensed the use of BioSante Pharmaceuticals' calcium phosphate nanoparticle technology as an adjuvant in its Chlamydophila pneumonia vaccine
  • 14 May 1999 Preclinical development for Chlamydial infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top